"Drug Synergism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug in promoting or enhancing the effectiveness of another drug.
| Descriptor ID |
D004357
|
| MeSH Number(s) |
G07.690.773.968.477
|
| Concept/Terms |
Drug Synergism- Drug Synergism
- Drug Synergisms
- Synergism, Drug
- Synergisms, Drug
Drug Potentiation- Drug Potentiation
- Drug Potentiations
- Potentiation, Drug
- Potentiations, Drug
Drug Augmentation- Drug Augmentation
- Augmentation, Drug
- Augmentations, Drug
- Drug Augmentations
|
Below are MeSH descriptors whose meaning is more general than "Drug Synergism".
Below are MeSH descriptors whose meaning is more specific than "Drug Synergism".
This graph shows the total number of publications written about "Drug Synergism" by people in this website by year, and whether "Drug Synergism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 4 | 4 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 4 | 4 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 4 | 4 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 6 | 6 |
| 2004 | 0 | 5 | 5 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 9 | 9 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 9 | 9 |
| 2009 | 0 | 6 | 6 |
| 2010 | 0 | 4 | 4 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 7 | 7 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 6 | 6 |
| 2016 | 0 | 10 | 10 |
| 2017 | 0 | 9 | 9 |
| 2018 | 1 | 4 | 5 |
| 2019 | 1 | 11 | 12 |
| 2020 | 0 | 9 | 9 |
| 2021 | 0 | 7 | 7 |
| 2025 | 0 | 2 | 2 |
| 2026 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Synergism" by people in Profiles.
-
Candesartan cilexetil disrupts methicillin-resistant Staphylococcus aureus membrane and potentiates gentamicin and polymyxin B activity. Nat Commun. 2026 Mar 15; 17(1).
-
Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing Klebsiella pneumoniae in the hollow fiber infection model. Antimicrob Agents Chemother. 2026 04; 70(4):e0136525.
-
Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-?-lactamase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2026 Mar 04; 70(3):e0154025.
-
Synergistic Effects of Honokiol on Camptothecin-triggered Apoptosis of Drug-resistant Glioblastoma Cells via CDK1-mediated G2/M Arrest and Intrinsic ROS-Mitochondrion-dependent Pathway. Anticancer Res. 2026 Feb; 46(2):633-649.
-
Magnolol Traverses the Blood-brain Barrier and Enhances Temozolomide-induced Intrinsic Apoptosis of Glioblastoma Cells via a p53 Redox Signaling Mechanism. Anticancer Res. 2025 Nov; 45(11):5001-5017.
-
Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma. Cancer Lett. 2025 Aug 10; 625:217814.
-
Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. Pigment Cell Melanoma Res. 2022 01; 35(1):66-77.
-
Curcumin-laden hyaluronic acid-co-Pullulan-based biomaterials as a potential platform to synergistically enhance the diabetic wound repair. Int J Biol Macromol. 2021 Aug 31; 185:350-368.
-
Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling. Mol Cancer Ther. 2021 08; 20(8):1469-1480.
-
Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. Mol Cancer Ther. 2021 07; 20(7):1257-1269.